CL2007001902A1 - Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas. - Google Patents

Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.

Info

Publication number
CL2007001902A1
CL2007001902A1 CL200701902A CL2007001902A CL2007001902A1 CL 2007001902 A1 CL2007001902 A1 CL 2007001902A1 CL 200701902 A CL200701902 A CL 200701902A CL 2007001902 A CL2007001902 A CL 2007001902A CL 2007001902 A1 CL2007001902 A1 CL 2007001902A1
Authority
CL
Chile
Prior art keywords
aggregation
disorder
plates
treatment
pharmaceutical composition
Prior art date
Application number
CL200701902A
Other languages
English (en)
Inventor
Kay Zetterberg Fredr Brickmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38605551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001902(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2007001902A1 publication Critical patent/CL2007001902A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200701902A 2006-06-28 2007-06-27 Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas. CL2007001902A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0601412 2006-06-28
SE0601467 2006-07-04

Publications (1)

Publication Number Publication Date
CL2007001902A1 true CL2007001902A1 (es) 2008-04-04

Family

ID=38605551

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701902A CL2007001902A1 (es) 2006-06-28 2007-06-27 Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.

Country Status (16)

Country Link
US (2) US20070244088A1 (es)
EP (1) EP2041111A1 (es)
JP (1) JP2009542640A (es)
KR (1) KR20090034339A (es)
AR (1) AR061651A1 (es)
AU (1) AU2007265734A1 (es)
BR (1) BRPI0713367A2 (es)
CA (1) CA2655228A1 (es)
CL (1) CL2007001902A1 (es)
EC (1) ECSP088975A (es)
IL (1) IL195730A0 (es)
MX (1) MX2008016501A (es)
NO (1) NO20085218L (es)
TW (1) TW200815426A (es)
UY (1) UY30443A1 (es)
WO (1) WO2008002247A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118296A1 (en) * 2005-07-20 2009-05-07 Merck Frosst Canada Ltd. Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2011226773C1 (en) * 2007-04-27 2012-07-26 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
EP2604599A1 (en) 2007-04-27 2013-06-19 Purdue Pharma LP TRPV1 antagonists and uses thereof
AR074628A1 (es) * 2008-07-07 2011-02-02 Astrazeneca Ab Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308
AR072697A1 (es) * 2008-07-07 2010-09-15 Astrazeneca Ab Compuestos de piridina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastorno de agregacion plaquetaria
GB0902173D0 (en) 2009-02-10 2009-03-25 Takeda Pharmaceutical Compounds and their use
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 ３－（ビアリールオキシ）プロピオン酸誘導体
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
BR112012030184A2 (pt) * 2010-05-27 2015-12-29 Bayer Cropscience Ag derivados de ácido piridinilcarboxílico como fungicidas
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
US9289209B2 (en) 2011-06-09 2016-03-22 Covidien Lp Surgical fastener applying apparatus
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9539246B2 (en) 2011-08-30 2017-01-10 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
LT2800743T (lt) 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
EP2956441A4 (en) * 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
ES2807582T3 (es) 2013-07-11 2021-02-23 Agios Pharmaceuticals Inc Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
CA3090020A1 (en) 2018-03-02 2019-09-06 Covidien Lp Surgical stapling instrument
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US11278282B2 (en) 2020-01-31 2022-03-22 Covidien Lp Stapling device with selective cutting
US11517305B2 (en) 2020-07-09 2022-12-06 Covidien Lp Contoured staple pusher
US11517313B2 (en) 2021-01-27 2022-12-06 Covidien Lp Surgical stapling device with laminated drive member
JP2024512931A (ja) * 2021-03-18 2024-03-21 シロナックス リミテッド． 受容体相互作用タンパク質１阻害剤、その調製、及び使用
CN118076585A (zh) * 2021-07-23 2024-05-24 国家医疗保健研究所 革兰氏阴性菌外排泵抑制剂
US11540831B1 (en) 2021-08-12 2023-01-03 Covidien Lp Staple cartridge with actuation sled detection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2664238B2 (ja) * 1989-03-01 1997-10-15 日清製粉株式会社 ニコチン酸またはそのエステル誘導体
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
EA200700117A1 (ru) * 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
WO2006006741A1 (ja) * 2004-07-15 2006-01-19 Japan Tobacco Inc. 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
AU2007270083A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues

Also Published As

Publication number Publication date
TW200815426A (en) 2008-04-01
KR20090034339A (ko) 2009-04-07
EP2041111A1 (en) 2009-04-01
NO20085218L (no) 2009-01-12
WO2008002247A1 (en) 2008-01-03
AU2007265734A1 (en) 2008-01-03
ECSP088975A (es) 2009-01-30
JP2009542640A (ja) 2009-12-03
AR061651A1 (es) 2008-09-10
BRPI0713367A2 (pt) 2012-03-13
US20070244088A1 (en) 2007-10-18
US20090186876A1 (en) 2009-07-23
CA2655228A1 (en) 2008-01-03
IL195730A0 (en) 2009-09-01
MX2008016501A (es) 2009-01-21
UY30443A1 (es) 2008-01-31

Similar Documents

Publication Publication Date Title
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
DK2399580T3 (da) Farmaceutiske doseringsformer
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas